These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37935466)

  • 1. Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform Infection in Inflammatory Bowel Disease Patients.
    González Cueto E; Edmans M; Wellens J; Cadwell K; Thompson C; Satsangi J; Wong SY;
    Inflamm Bowel Dis; 2024 May; 30(5):859-862. PubMed ID: 37935466
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection.
    Hoyois A; Gulkilik C; Mekkaoui L; Dahma H; Wambacq V; Minsart C; Rosewick N; Liefferinckx C; Amininejad L; Van Gossum A; Cremer A; Vandenberg O; Franchimont D
    Acta Gastroenterol Belg; 2024; 87(2):263-273. PubMed ID: 39210758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease.
    Brenner EJ; Weaver KN; Zhang X; Kastl AJ; Strople JA; Adler J; Dubinsky MC; Bousvaros A; Watkins R; Dai X; Chen W; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda EA; Farraye FA; Chun KY; Zikry M; Bastidas M; Firestine A; Craig RG; Boccieri ME; Long MD; Kappelman MD
    Clin Gastroenterol Hepatol; 2024 Jul; 22(7):1475-1486.e4. PubMed ID: 38369224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.
    Connolly CM; Teles M; Frey S; Boyarsky BJ; Alejo JL; Werbel WA; Albayda J; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
    Ann Rheum Dis; 2022 Feb; 81(2):291-293. PubMed ID: 34493492
    [No Abstract]   [Full Text] [Related]  

  • 8. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant.
    Parry H; Tut G; Bruton R; Faustini S; Stephens C; Saunders P; Bentley C; Hilyard K; Brown K; Amirthalingam G; Charlton S; Leung S; Chiplin E; Coombes NS; Bewley KR; Penn EJ; Rowe C; Otter A; Watts R; D'Arcangelo S; Hallis B; Makin A; Richter A; Zuo J; Moss P
    Elife; 2021 Sep; 10():. PubMed ID: 34586068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral and Cellular Immune Response to SARS-CoV-2 S and N Proteins.
    Afridonova ZE; Toptygina AP; Mikhaylov IS
    Biochemistry (Mosc); 2024 May; 89(5):872-882. PubMed ID: 38880648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.
    Lim SH; Campbell N; Johnson M; Joseph-Pietras D; Collins GP; O'Callaghan A; Fox CP; Ahearne M; Johnson PWM; Goldblatt D; Davies AJ
    Lancet Haematol; 2021 Aug; 8(8):e542-e544. PubMed ID: 34224667
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study).
    Casas Deza D; Julián Gomara AB; Caudevilla Biota E; Beltrán B; Domènech E; Gutiérrez Casbas A; Mañosa M; Zabana Y; Roc Alfaro L; Valverde Romero E; García González E; Sicilia B; Laredo V; Alcalá Escriche MJ; Madero Velázquez L; Ferreiro-Iglesias R; Palmero Pérez A; Calafat M; Rubio Iturria S; Moraleja Yudego I; Ber Nieto Y; García Mateo S; Gisbert JP; Vicente Lidón R; Arias L; Alfambra E; Doñate Borao AB; Peña González E; Corsino Roche P; Vicuña Arregui M; Elorza A; Domínguez Cajal M; Chaparro M; Barreiro-de Acosta M; García-López S
    Gastroenterol Hepatol; 2024; 47(7):750-758. PubMed ID: 38219960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.
    Macaluso FS; Principi M; Facciotti F; Contaldo A; Todeschini A; Saibeni S; Bezzio C; Castiglione F; Nardone OM; Spagnuolo R; Fantini MC; Riguccio G; Conforti S; Caprioli F; Viganò C; Felice C; Fiorino G; Correale C; Bodini G; Milla M; Scardino G; Vernero M; Desideri F; Bossa F; Guerra M; Ventimiglia M; Casà A; Rizzo G; Orlando A;
    Inflamm Bowel Dis; 2024 May; 30(5):854-858. PubMed ID: 37390400
    [No Abstract]   [Full Text] [Related]  

  • 15. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
    Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
    Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Wagenhäuser I; Almanzar G; Förg FB; Stein A; Eiter I; Reusch J; Mees J; Herzog A; Vogel U; Frey A; Lâm TT; Schubert-Unkmeir A; Dölken L; Kurzai O; Frantz S; Gabel A; Petri N; Prelog M; Krone M
    Vaccine; 2024 Aug; 42(21):126132. PubMed ID: 39034219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection.
    Bhavsar D; Singh G; Sano K; Gleason C; Srivastava K; ; Carreno JM; Simon V; Krammer F
    mBio; 2023 Dec; 14(6):e0228023. PubMed ID: 38092666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population.
    Vanamudhu A; Devi Arumugam R; Nancy A; Selvaraj N; Moiden K; Hissar S; Ranganathan UD; Bethunaickan R; Babu S; Kumar NP
    Viruses; 2024 Jul; 16(8):. PubMed ID: 39205152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
    Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
    Front Immunol; 2021; 12():727850. PubMed ID: 34671350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.
    Caldera F; Rolak S; Farraye FA; Necela BM; Cogen D; Zona EE; Schell TL; Ramirez OR; Almasry M; Chun K; Hayney MS; Knutson KL
    Clin Transl Gastroenterol; 2024 Apr; 15(4):e00688. PubMed ID: 38349178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.